Tempest Therapeutics Stock Forward View
| TPST Stock | USD 2.40 0.01 0.42% |
News-driven analysis for Tempest Therapeutics seeks to separate meaningful signals from market noise. By filtering relevant headlines and sentiment trends, this module identifies potential catalysts that may move Tempest Therapeutics' price.
At the latest evaluation, Tempest Therapeutics posts the 14-period RSI reading of 44, reflecting mild downside bias. This range suggests moderated price movement without extreme directional pressure.Momentum
Sell Extended
Oversold | Overbought |
EPS Estimate Next Quarter -3.52 | EPS Estimate Current Year -6.10 | EPS Estimate Next Year -2.76 | Wall Street Target Price 11 | EPS Estimate Current Quarter -3.27 |
The hype-based summary links Tempest Therapeutics attention patterns with price response and peers.
The Naive Prediction forecasted value of Tempest Therapeutics on the next trading day is expected to be 2.44 with a mean absolute deviation of 0.09 and the sum of the absolute errors of 5.80.Tempest Therapeutics after-hype prediction price | $ 2.39 |
Attention metrics here are presented with forecasting, technical, analyst, and earnings context.
Historical Fundamental Analysis of Tempest Therapeutics provides a cross-check on projections for Tempest Therapeutics. The view provides historical context for the projection set.Tempest Therapeutics Additional Predictive Modules
Most predictive techniques to examine Tempest price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Tempest using various technical indicators. When you analyze Tempest charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Tempest Therapeutics Cash Forecast
The quality of a cash forecast for Tempest Therapeutics depends on the accuracy of underlying assumptions about Tempest Therapeutics' revenue, costs, and working capital trends derived from its historical financial statements.
Cash | First Reported 2012-06-30 | Previous Quarter 14.3 M | Current Value 7.5 M | Quarterly Volatility 23.3 M |
Macro event markers
Tempest Therapeutics Naive Prediction Price Forecast For the 12th of March 2026
Given 90 days horizon, the Naive Prediction forecasted value of Tempest Therapeutics on the next trading day is expected to be 2.44 with a mean absolute deviation of 0.09 , mean absolute percentage error of 0.01 , and the sum of the absolute errors of 5.80 .Please note that although there have been many attempts to predict Tempest Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Tempest Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Tempest Therapeutics Stock Forecast Pattern
| Backtest Tempest Therapeutics | Tempest Therapeutics Price Prediction | Research Analysis |
Tempest Therapeutics Forecasted Value
This next-day forecast for Tempest Therapeutics uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Tempest Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Tempest Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 115.7448 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0935 |
| MAPE | Mean absolute percentage error | 0.035 |
| SAE | Sum of the absolute errors | 5.7978 |
Mean reversion in Tempest Therapeutics is more reliable over longer time horizons. Short-term deviations can persist and even widen before correcting, making position sizing and risk management critical.
Tempest Therapeutics After-Hype Price Density Analysis
Investors who rely solely on expected value estimates for Tempest Therapeutics miss the full picture. Tempest Therapeutics' probability distribution reveals that expected value can be achieved through very different combinations of outcomes, each with different risk implications.
Next price density |
| Expected price to next headline |
Tempest Therapeutics Estimiated After-Hype Price Volatility
The after-news price analysis for Tempest Therapeutics is built on the observation that Tempest Therapeutics' market reactions to news are not random but follow recognizable patterns. Tempest Therapeutics' after-hype downside and upside margins for the prediction period are 0.12 and 6.38, respectively. Identifying and quantifying these patterns for Tempest Therapeutics is the core purpose of this model.
Current Value
The after-hype framework applied to Tempest Therapeutics assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Tempest Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Tempest Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tempest Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Tempest Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.38 | 4.02 | 0.01 | 0.31 | 6 Events | 2 Events | In 6 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
2.40 | 2.39 | 0.42 |
|
Tempest Therapeutics Hype Timeline
Tempest Therapeutics is at this time traded for 2.40. The company has historical hype elasticity of -0.01, and average elasticity to hype of competition of -0.31. Tempest is projected to decline in value after the next headline, with the price expected to drop to 2.39. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.42%, whereas the daily expected return is at this time at -0.38%. The volatility of related hype on Tempest Therapeutics is about 488.75%, with the expected price after the next announcement by competition of 2.09. About 37.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 9.73. Tempest Therapeutics last dividend was issued on the 10th of December 2018. The company completed a 1:13 stock split on 9th of April 2025. Given the investment horizon of 90 days the next projected press release will be in 6 days. Historical Fundamental Analysis of Tempest Therapeutics provides a cross-check on projections for Tempest Therapeutics. The view provides historical context for the projection set.Tempest Therapeutics Related Hype Analysis
The information ratio and semi-deviation metrics in the peer comparison table for Tempest Therapeutics provide a risk-adjusted view of how efficiently Tempest Therapeutics' competitors convert news exposure into returns relative to downside risk.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| WAMFX | Walden Midcap Fund | 0.00 | 0 per month | 0.55 | 0.09 | 1.35 | -1.03 | 8.33 | |
| ASYS | Amtech Systems | -0.54 | 9 per month | 6.54 | 0.13 | 7.59 | -6.85 | 47.60 | |
| SRAD | Sportradar Group AG | 0.04 | 12 per month | 0.00 | -0.11 | 3.38 | -4.19 | 16.98 | |
| MRSK | Northern Lights | 0.93 | 2 per month | 0.83 | 0.01 | 1.10 | -1.37 | 3.63 | |
| AMYZF | American Manganese | 0.00 | 0 per month | 0.00 | -0.13 | 11.25 | -11.70 | 34.02 | |
| SITKF | Sitka Gold Corp | 0.00 | 0 per month | 2.82 | 0.06 | 7.81 | -5.71 | 17.28 | |
| GJUN | First Trust Exchange Traded | -0.01 | 2 per month | 0.20 | 0.07 | 0.38 | -0.33 | 1.28 | |
| IDCC | InterDigital | -7.00 | 7 per month | 2.47 | 0.05 | 5.09 | -3.67 | 16.69 |
Other Forecasting Options for Tempest Therapeutics
For investors considering Tempest, Tempest Therapeutics' price movement is the most direct driver of investment returns. Noise in Tempest Stock price charts can make identifying meaningful trends difficult without dedicated analytical tools.Tempest Therapeutics Related Equities
The following equities are related to Tempest Therapeutics within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Tempest Therapeutics against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Tempest Therapeutics Market Strength Events
Market strength indicators for Tempest Therapeutics provide investors with a view of how the stock performs across different market environments. By analyzing these indicators, traders can determine the best moments to enter or exit positions in Tempest Therapeutics.
Tempest Therapeutics Risk Indicators
A structured analysis of Tempest Therapeutics' risk indicators is one of the most reliable ways to improve the accuracy of price forecasts. Understanding the risk embedded in Tempest Therapeutics' allows investors to decide whether to accept, reduce, or hedge their exposure.
| Mean Deviation | 2.85 | |||
| Standard Deviation | 4.04 | |||
| Variance | 16.34 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Tempest Therapeutics
Coverage intensity for Tempest Therapeutics matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Tempest Therapeutics Short Properties
Short sentiment tied to Tempest Therapeutics matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 27.9 M | |
| Cash And Short Term Investments | 30.3 M |
Additional Tools for Tempest Stock Analysis
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |